Belgian Investment Company for Developing Countries [8] (BIO) is supporting the development of high-quality pharmaceutical manufacturing in Tanzania by providing a US$2.5 million long-term financing to Zenufa [9], a company that is setting-up one of the first Tanzanian pharmaceutical plant complying with the WHO Current Good Manufacturing Standards.

This investment will allow to renovate unoccupied former premises, to equip the plant and bring the site to CGMP-standards [10] (Current Good Manufacturing Practice). The Sponsors are experienced in manufacturing and distributing pharmaceutical products in Africa and will provide half of the financing needed for the project. The plant will manufacture generic [11] drugs including antibiotics, anti-malaria [12]- and anti-parasite [13] drugs, drugs against pain and fever, etc.

Although the economic growth in Tanzania is very encouraging, aid epidemics are a constant threat to the country. Thanks to the government and international donors support access to health care has been improved. Zenufa has a long-range plan to produce more innovative drugs, not yet manufactured in Tanzania, such as ARV drugs for aids patients. Zenufa will sell most of its products in Tanzania but will also target other neighbourhood countries.

The creation of this pharmaceutical plant in Tanzania will improve the access to essential drugs, will help reduce prices and will offer opportunities to launch more sophisticated drugs. Moreover Zenufa will create about 150 new jobs, most of them for women. Zenufa also pays much attention to environmental aspects and the project has been designed to mitigate major environmental impacts. Zenufa will also have an important development impact by professionalizing the supply chain, stimulating the demand and raising the quality standards.